Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort

Jennifer St. Sauver, Aruna V. Sarma, Debra J. Jacobson, Michaela E. McGree, Michael M. Lieber, Cynthia J. Girman, Ajay Nehra, Steven J. Jacobsen

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Inflammation may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract symptoms (LUTS). Higher levels of C-reactive protein (CRP) may therefore be associated with the development of these outcomes. The authors examined the association of CRP levels measured in 1996 with rapid increases in prostate volume, prostate-specific antigen levels, and LUTS as well as rapid decreases in peak flow rates (through 2005) in a population-based cohort of men residing in Olmsted County, Minnesota. Men with CRP levels of ≥3.0 mg/L were more likely to have rapid increases in irritative LUTS (odds ratio (OR)=2.14, 95% confidence interval (CI): 1.18, 3.85) and rapid decreases in peak flow rates (OR=2.54, 95% CI: 1.09, 5.92) compared with men with CRP levels of <3.0 mg/L. CRP levels were not significantly associated with rapid increases in prostate volume, obstructive LUTS, or prostate-specific antigen levels. Associations were attenuated after adjusting for age, body mass index, hypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.04, 3.82; peak flow rate: OR = 2.45, 95% CI: 0.73, 8.25). These results suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due to inflammatory processes.

Original languageEnglish (US)
Pages (from-to)1281-1290
Number of pages10
JournalAmerican Journal of Epidemiology
Volume169
Issue number11
DOIs
StatePublished - Jun 2009

Fingerprint

Lower Urinary Tract Symptoms
Prostatic Hyperplasia
C-Reactive Protein
Odds Ratio
Confidence Intervals
Population
Prostate-Specific Antigen
Prostate
Body Mass Index
Smoking
History
Hypertension
Inflammation

Keywords

  • C-reactive protein
  • Inflammation
  • Prostatic hyperplasia
  • Signs and symptoms
  • Urinary tract

ASJC Scopus subject areas

  • Epidemiology

Cite this

Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. / St. Sauver, Jennifer; Sarma, Aruna V.; Jacobson, Debra J.; McGree, Michaela E.; Lieber, Michael M.; Girman, Cynthia J.; Nehra, Ajay; Jacobsen, Steven J.

In: American Journal of Epidemiology, Vol. 169, No. 11, 06.2009, p. 1281-1290.

Research output: Contribution to journalArticle

St. Sauver, Jennifer ; Sarma, Aruna V. ; Jacobson, Debra J. ; McGree, Michaela E. ; Lieber, Michael M. ; Girman, Cynthia J. ; Nehra, Ajay ; Jacobsen, Steven J. / Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. In: American Journal of Epidemiology. 2009 ; Vol. 169, No. 11. pp. 1281-1290.
@article{d2ed139725364fc090c06aa2f12e3e91,
title = "Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort",
abstract = "Inflammation may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract symptoms (LUTS). Higher levels of C-reactive protein (CRP) may therefore be associated with the development of these outcomes. The authors examined the association of CRP levels measured in 1996 with rapid increases in prostate volume, prostate-specific antigen levels, and LUTS as well as rapid decreases in peak flow rates (through 2005) in a population-based cohort of men residing in Olmsted County, Minnesota. Men with CRP levels of ≥3.0 mg/L were more likely to have rapid increases in irritative LUTS (odds ratio (OR)=2.14, 95{\%} confidence interval (CI): 1.18, 3.85) and rapid decreases in peak flow rates (OR=2.54, 95{\%} CI: 1.09, 5.92) compared with men with CRP levels of <3.0 mg/L. CRP levels were not significantly associated with rapid increases in prostate volume, obstructive LUTS, or prostate-specific antigen levels. Associations were attenuated after adjusting for age, body mass index, hypertension, and smoking history (irritative LUTS: OR = 2.00, 95{\%} CI: 1.04, 3.82; peak flow rate: OR = 2.45, 95{\%} CI: 0.73, 8.25). These results suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due to inflammatory processes.",
keywords = "C-reactive protein, Inflammation, Prostatic hyperplasia, Signs and symptoms, Urinary tract",
author = "{St. Sauver}, Jennifer and Sarma, {Aruna V.} and Jacobson, {Debra J.} and McGree, {Michaela E.} and Lieber, {Michael M.} and Girman, {Cynthia J.} and Ajay Nehra and Jacobsen, {Steven J.}",
year = "2009",
month = "6",
doi = "10.1093/aje/kwp085",
language = "English (US)",
volume = "169",
pages = "1281--1290",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort

AU - St. Sauver, Jennifer

AU - Sarma, Aruna V.

AU - Jacobson, Debra J.

AU - McGree, Michaela E.

AU - Lieber, Michael M.

AU - Girman, Cynthia J.

AU - Nehra, Ajay

AU - Jacobsen, Steven J.

PY - 2009/6

Y1 - 2009/6

N2 - Inflammation may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract symptoms (LUTS). Higher levels of C-reactive protein (CRP) may therefore be associated with the development of these outcomes. The authors examined the association of CRP levels measured in 1996 with rapid increases in prostate volume, prostate-specific antigen levels, and LUTS as well as rapid decreases in peak flow rates (through 2005) in a population-based cohort of men residing in Olmsted County, Minnesota. Men with CRP levels of ≥3.0 mg/L were more likely to have rapid increases in irritative LUTS (odds ratio (OR)=2.14, 95% confidence interval (CI): 1.18, 3.85) and rapid decreases in peak flow rates (OR=2.54, 95% CI: 1.09, 5.92) compared with men with CRP levels of <3.0 mg/L. CRP levels were not significantly associated with rapid increases in prostate volume, obstructive LUTS, or prostate-specific antigen levels. Associations were attenuated after adjusting for age, body mass index, hypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.04, 3.82; peak flow rate: OR = 2.45, 95% CI: 0.73, 8.25). These results suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due to inflammatory processes.

AB - Inflammation may play a role in the development of benign prostatic hyperplasia and/or lower urinary tract symptoms (LUTS). Higher levels of C-reactive protein (CRP) may therefore be associated with the development of these outcomes. The authors examined the association of CRP levels measured in 1996 with rapid increases in prostate volume, prostate-specific antigen levels, and LUTS as well as rapid decreases in peak flow rates (through 2005) in a population-based cohort of men residing in Olmsted County, Minnesota. Men with CRP levels of ≥3.0 mg/L were more likely to have rapid increases in irritative LUTS (odds ratio (OR)=2.14, 95% confidence interval (CI): 1.18, 3.85) and rapid decreases in peak flow rates (OR=2.54, 95% CI: 1.09, 5.92) compared with men with CRP levels of <3.0 mg/L. CRP levels were not significantly associated with rapid increases in prostate volume, obstructive LUTS, or prostate-specific antigen levels. Associations were attenuated after adjusting for age, body mass index, hypertension, and smoking history (irritative LUTS: OR = 2.00, 95% CI: 1.04, 3.82; peak flow rate: OR = 2.45, 95% CI: 0.73, 8.25). These results suggest that rapid increases in irritative LUTS and rapid decreases in peak flow rates may be due to inflammatory processes.

KW - C-reactive protein

KW - Inflammation

KW - Prostatic hyperplasia

KW - Signs and symptoms

KW - Urinary tract

UR - http://www.scopus.com/inward/record.url?scp=66249110329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66249110329&partnerID=8YFLogxK

U2 - 10.1093/aje/kwp085

DO - 10.1093/aje/kwp085

M3 - Article

VL - 169

SP - 1281

EP - 1290

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 11

ER -